What did @beingmarcellahill actually say?
Marcella Hill has been using testosterone pellets for two and a half years, describing them as having "completely saved my life" by restoring energy, libido, and skin comfort. She switched to injections primarily to avoid the post-insertion recovery window that would interrupt her training program. After one month on injections, she reports that nearly all her symptoms have returned: bone pain, poor sleep, itching, and absent libido. She suspects the dose is too low and admits she has been inconsistent with her injection schedule. She plans to reassess after blood work and potentially return to pellets.
She also listed androgenic side effects she experienced at high pellet doses, including hair thinning, clitoral enlargement, voice deepening, and chin hair growth, framing them as acceptable trade-offs at lower severity levels. This is a personal hormone optimization narrative, not medical advice, and she is transparent about that framing throughout.
Does the science back this up?
Mostly yes, with some important nuances. The pharmacokinetic difference between pellets and injections is real and well-documented. Pellets release testosterone steadily over 3 to 6 months, while subcutaneous or intramuscular injections produce peaks and troughs depending on frequency and ester. Her symptom return is consistent with what happens when testosterone levels drop.
The androgenic side effects she lists, specifically voice deepening, clitoral enlargement, and hirsutism, are documented in the literature on testosterone therapy in women at supraphysiologic doses. Davis et al. (2019, The Lancet Diabetes and Endocrinology) reviewed testosterone use in women and confirmed these effects are dose-dependent and largely, though not always, reversible. What is less well-established is the idea that pellets are categorically superior for symptom management. A 2022 study by Donovitz and Cotten in the Journal of Personalized Medicine found patient-reported outcomes favored pellets over other delivery methods, but that study had significant industry ties and methodological limitations worth noting. The evidence base for pellet therapy remains thinner than for injections or gels.
What did they get wrong (or right)?
She got the androgenic side effect list right. The effects she described, "your hair can fall out, your clitoris can get bigger, your voice can deepen," are clinically recognized and documented when testosterone in women exceeds physiologic ranges. Credit where it is due: she named them plainly without minimizing.
What she gets wrong, or at least oversimplifies, is the framing that injections are failing her after one month of inconsistent use. Inconsistent injection timing is almost certainly the primary variable here, not the delivery method itself. Skipping doses and injecting on irregular days will produce erratic serum levels, which explains her symptom return far better than any inherent inferiority of injections. She acknowledges this herself but does not give it enough weight. Her plan to get blood work is the right call. Without knowing her actual testosterone levels, drawing conclusions about whether injections "work" is premature.
She also does not mention that pellet dosing is harder to adjust quickly if levels go too high. That is a real clinical limitation that her framing of pellets as the gold standard glosses over.
What should you actually know?
Testosterone delivery method matters, but consistency matters more. For women, supraphysiologic testosterone levels from any delivery method carry real androgenic risks, and those risks are not always fully reversible. Voice changes, for example, may persist even after dose reduction. Davis et al. (2019) specifically flagged permanent voice changes as an underreported concern in women on testosterone therapy.
Pellets do offer convenience and steady-state levels, but they also lock you into a dose for months with limited ability to adjust. If levels climb too high, you cannot simply stop the pellet. Injections, by contrast, give a prescriber more flexibility to titrate. For women specifically, the Endocrine Society and ISSWSH (International Society for the Study of Women's Sexual Health) both recommend that testosterone therapy stay within physiologic female reference ranges. Neither organization currently endorses supraphysiologic dosing for symptom management, though some clinicians practice outside those guidelines.
If you are considering switching delivery methods, do it with consistent technique and timing before concluding the new method is not working. One month of irregular injections is not a fair trial.